Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Sunday, June 30, 2024.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2024 (2024-06-30): -171.09%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-119.18%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Estrella Immunopharma, Inc.
Market Cap
$18.30M
Return on Equity (ROE)
N/A
TTM Avg
-119.18%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$18.41M
Return on Equity (ROE)
-136.36%
TTM Avg
-41.80%
3Y Avg
-1184.66%
5Y Avg
-795.29%
Market Cap
$18.65M
Return on Equity (ROE)
-75.34%
TTM Avg
-0.67%
3Y Avg
-77.39%
5Y Avg
-61.36%
Market Cap
$17.39M
Return on Equity (ROE)
-117.98%
TTM Avg
-84.94%
3Y Avg
-64.05%
5Y Avg
-76.29%
Market Cap
$17.31M
Return on Equity (ROE)
-54.45%
TTM Avg
-33.23%
3Y Avg
-44.23%
5Y Avg
-52.50%
Market Cap
$19.42M
Return on Equity (ROE)
-2067.81%
TTM Avg
-13234.78%
3Y Avg
-6645.16%
5Y Avg
-6645.16%
Market Cap
$16.84M
Return on Equity (ROE)
-71.57%
TTM Avg
-65.12%
3Y Avg
-85.39%
5Y Avg
-90.29%
Market Cap
$19.77M
Return on Equity (ROE)
-313.46%
TTM Avg
-251.20%
3Y Avg
-178.74%
5Y Avg
-144.62%
Market Cap
$16.82M
Return on Equity (ROE)
-170.55%
TTM Avg
-79.16%
3Y Avg
-71.01%
5Y Avg
-42.13%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | $18.30M | N/A | -119.18% | N/A | N/A |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | -136.36% | -41.80% | -1184.66% | -795.29% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | -75.34% | -0.67% | -77.39% | -61.36% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | -117.98% | -84.94% | -64.05% | -76.29% |
| Lipocine Inc. (LPCN)vs › | $17.31M | -54.45% | -33.23% | -44.23% | -52.50% |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | -2067.81% | -13234.78% | -6645.16% | -6645.16% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | -71.57% | -65.12% | -85.39% | -90.29% |
| Quantum BioPharma Ltd. (QNTM)vs › | $19.77M | -313.46% | -251.20% | -178.74% | -144.62% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | -170.55% | -79.16% | -71.01% | -42.13% |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | -125.30% | 118.50% | 7030.24% | 4638.47% |
ROE
N/A
ROA
-548.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-06-30 | -171.09% |
| 2024-03-31 | -71.72% |
| 2023-12-31 | -92.43% |
| 2023-09-30 | -100.30% |
| 2023-06-30 | -160.35% |
| 2023-03-31 | -134.96% |
| 2022-12-31 | -97.36% |
| 2022-09-30 | -9.77% |
| 2022-06-30 | -3.33% |
| 2022-03-31 | -0.87% |
